|Articles|January 23, 2023
At-line Spent Media Analysis using the REBEL to Optimize a CHO mAb Fed-Batch Process
Author(s)908 Devices
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FAQ: What You Need to Know About Agentic AI in Drug Discovery
2
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
3
HHS Releases New Guidance on Lowering Prescription Drug Prices Through DTC Programs
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5